A KEI note to Library of Congress about ACTA text

From: James Love
To: Michele Woods
Cc: Nancy Weiss
Subject: Some examples of US inconsistency with ACTA
Date: Fri, 12 Nov 2010 07:29:09 -0500

This note cites several areas where US law is plainly inconsistent with
ACTA.

In addition, in a separate analysis,I have called attention to proposed
legislation in USA on orphan copyrighted works that are very
inconsistent with ACTA provisions on remedies.
https://www.keionline.org/node/980

Some examples of inconsistencies between ACTA and US law

Continue Reading

Uncategorized

KEI statement at SCCR 21

This was our 400 word statement at the WIPO SCCR 21.

Statement of KEI at WIPO SCCR 21, November 11, 2010

There should be a compelling rationale for creating new global norms for copyrights.

KEI opposes work on a new broadcasting treaty, and supports work on performers treaty.

KEI supports work at the SCCR on new possible norms for copyright limitations and exceptions, particularly as regards to access to knowledge, and uses of new technologies.

Continue Reading

European generic drug companies ask EU Parliament to remove patents from ACTA

The European Generics Association has written to the European Parliament asking that patents be removed from the Anti-Counterfeiting Agreement. A PDF copy of their letter is here. The text in html follows:

MEP Mr. Gianluca Susta
INTA Committee
European Parliament
1049 Bruxelles- Belgium

Brussels, 5th of November 2010

Ref. EGA comments to the consolidated text on ACTA that reflects changes made during the

September 2010 Tokyo round1.

Dear Mr. Susta,

Continue Reading

Uncategorized

USTR positions in China WTO TRIPS dispute at odds with talking points on ACTA flexibility

Use of Article 1.1 of the TRIPS in the US/China WTO dispute over the enforcement of intellectual property rights

USTR claims that Article 1.2.1 of ACTA provides the flexibility to overlook inconsistencies between US law and ACTA. Below is the text from both Article 1.2.1 of ACTA, and Article 1.1 of TRIPS:

ACTA ARTICLE 1.2: NATURE AND SCOPE OF OBLIGATIONS
Continue Reading

Uncategorized

Michèle Rivasi asks question about ACTA and Access to Medicine

225px-michel-rivasi.jpg Michèle Rivasi, a Member of the European Parliament, representing South East France for The Greens, has asked the European Commission: “Given the possible impacts of the inclusion of patents the agreement on access to medicines and on innovation, would the Commission consider accepting the exclusion of patents from the agreement as proposed by a number of ACTA negotiating parties?” The full text of her question follows:

Continue Reading

Uncategorized